Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Xilio Therapeutics, Inc.NASDAQ: XLO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$9.53M, compared with -$13.27M a year earlier. Trailing-twelve-month income before tax was -$31.3M.

Context

  • Income before tax amounted to 80.1% of revenue in FY2025, down 838.0 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$9.53M or moves back toward the trailing-twelve-month quarterly average of -$7.83M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.53M-192.0% QoQ
Last fiscal yearDec 2025
-$35.04M+39.8% YoY
LTMMar 2026
-$31.3M+42.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.2%——
1 year+39.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(35.04M) USD
Year-over-year change
+39.8%

Income Before Tax vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 income before tax of -$31.3M is the 2nd highest of the 4 companies compared; the peer median is -$33.36M.
  • Its year-over-year change of +42.4% is the 2nd highest of 4, against a peer median of +14.8%.
  • Income before tax amounts to 58.5% of revenue for XLO, versus a peer median of 32.2%.
XLO Competitors Peer median
Income Before Tax for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$11.31M +127.6%—32.2%
XLOXilio Therapeutics, Inc.LTM Mar 2026-$31.3M +42.4%—58.5%
PDSBPDS Biotechnology CorporationLTM Mar 2026-$33.36M +11.1%——
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$58.75M +14.8%——
Peer median (excluding XLO) -$33.36M+14.8%—32.2%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.